谭建军 博士生导师、硕士生导师
联系电话：
E-mail：tanjianjun@bjut.edu.cn
通讯地址：北京市朝阳区平乐园100号
威尼斯wns.8885556威尼斯wns.8885556
教育背景
2001-09 至2007-07 威尼斯wns.8885556生命科学与生物工程学院，博士研究生。
1988-09 至1991-03 威尼斯wns.8885556化学与环境工程学系，硕士研究生。
1984-09 至1988-07 南京理工大学化学工程系，本科。
工作经历
2020-今 威尼斯wns.8885556威尼斯wns.8885556，教授
2017-2020 威尼斯wns.8885556生命科学与生物工程学院，教授
2005-2017 威尼斯wns.8885556生命科学与生物工程学院，副研究员
2002-2005 威尼斯wns.8885556生命科学与生物工程学院，讲师
1991-2005 威尼斯wns.8885556环境与能源工程学院，助教、讲师
研究方向
生物信息学
课程教学
主讲《生物医学统计》、《生物材料》、《生物信息学》、《学术报告》等课程
主要科研项目
(1) 北京市基金面上项目、2202002、用深度学习方法研究长链非编码RNA与蛋白质相互作用的分子机制、2020/01-2022/12、20万元、在研、主持。
(2) 国家自然科学基金面上项目、31971180、 基于全原子和粗粒化模型的蛋白质-RNA相互作用动力学及功能性构象变化的研究、2020/01-2023/12、69万元、在研、参加。
(3) 国家自然科学基金面上项目、21173014、抗HIV融合抑制剂的设计及其作用机理研究、2012/01-2015/12、61万元、结题、主持。
(4) 国家自然科学基金面上项目、31171267、基于RNA分子柔性分析的蛋白质-RNA分子对接方法研究、2012/01-2015/12、45万元、结题、参加。
(5) 国家重大基础研究发展计划（973计划）、2009CB930203、载药纳米颗粒的药效学、生物利用度及机理研究、2009/01-2013/08、672万元、已结题、参加。
(6) 科技部国际合作项目、2010DFA31710、纳米技术与理论计算相结合的环境监测方法合作研究、2010/06-2013/05、100万元、已结题、参加。
(7) 国家自然科学基金面上项目、30400087、蛋白质与蛋白质相互作用及对接方法的研究、2005/01-2007/12、22万元、已结题、参加。
(8) 国家自然科学基金面上项目、20042001、双区理论所揭示的致癌机理的实验证明和理论检验、2000/01-2002/12、8.8万元、已结题、参加。
(9) 国家自然科学基金面上项目、致癌机理双区理论的实验证明和理论检验、29742002、1997/05-1998/04、4万元、已结题、参加。
主要论文论著
[1] Men, J. R.; Tan, J. J.; Sun, H. L. The Identification and Analysis of a miRNA Risk Score Model for Hepatocellular Carcinoma Prognosis. Prog. Biochem. Biophys. 2020, 47 (4), 344-360, DOI: 10.16476/j.pibb.2019.0286.
[2] Tang, T.; Du, X. Y.; Zhang, X. Y.; Niu, W. L.; Li, C. H.; Tan, J. J. Computational identification and analysis of early diagnostic biomarkers for kidney cancer. J. Hum. Genet. 2019, 64 (10), 1015-1022, DOI: 10.1038/s10038-019-0640-2.
[3] Cheng, S. P.; Zhang, L.; Tan, J. J.; Gong, W. K.; Li, C. H.; Zhang, X. Y. DM-RPIs: Predicting ncRNA-protein interactions using stacked ensembling strategy. Comput. Biol. Chem. 2019, 83, DOI: 10.1016/j.compbiolchem.2019.107088.
[4] Liu, W.; An, X.; Wang, J.; Zhang, X.; Tan, J.; Zhou, Z.; Zeng, Y. A novel peptide shows excellent anti-HIV-1 potency as a gp41 fusion inhibitor. Bioorg Med Chem Lett 2018, 28 (5), 910-914, DOI: 10.1016/j.bmcl.2018.01.061.
[5] Zhang, Z.; Lu, L.; Zhang, Y.; Hua Li, C.; Wang, C. X.; Zhang, X. Y.; Tan, J. J. A combinatorial scoring function for protein-RNA docking. Proteins 2017, 85 (4), 741-752, DOI: 10.1002/prot.25253.
[6] Zhang, L.; Tan, J.; Han, D.; Zhu, H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov. Today 2017, 22 (11), 1680-1685, DOI: 10.1016/j.drudis.2017.08.010.
[7] Lv, D.; Wang, C.; Li, C.; Tan, J.; Zhang, X. An efficient perturbation method to predict the functionally key sites of glutamine binding protein. Comput. Biol. Chem. 2017, 67, 62-68, DOI: 10.1016/j.compbiolchem.2016.12.003.
[8] Tan, J.; Yuan, H.; Li, C.; Zhang, X.; Wang, C. Insights into the Functions of M-T Hook Structure in HIV Fusion Inhibitor Using Molecular Modeling. Comput. Biol. Chem. 2016, 61, 202-9, DOI: 10.1016/j.compbiolchem.2016.01.006.
[9] Tan, J.; Su, M.; Zeng, Y.; Wang, C. Design, synthesis and activity evaluation of novel peptide fusion inhibitors targeting HIV-1 gp41. Bioorg. Med. Chem. 2016, 24 (2), 201-206, DOI: http://dx.doi.org/10.1016/j.bmc.2015.12.003.
[10] Lv, D. S.; Li, C. H.; Tan, J. J.; Zhang, X. Y.; Wang, C. X.; Su, J. G. Identification of functionally key residues in maltose transporter with an elastic network model-based thermodynamic method. Mol. Phys. 2016, 114 (22), 3407-3417, DOI: 10.1080/00268976.2016.1234077.
[11] Han, D.; Su, M.; Tan, J. J.; Li, C. H.; Zhang, X. Y.; Wang, C. X. Structure-activity relationship and binding mode studies for a series of diketo-acids as HIV integrase inhibitors by 3D-QSAR, molecular docking and molecular dynamics simulations. Rsc Adv 2016, 6 (33), 27594-27606, DOI: 10.1039/c6ra00713a.
[12] Xie, X. L.; Li, C. H.; Yang, Y. X.; Jin, L.; Tan, J. J.; Zhang, X. Y.; Su, J. G.; Wang, C. X. Allosteric transitions of ATP-binding cassette transporter MsbA studied by the adaptive anisotropic network model. Proteins 2015, 83 (9), 1643-53, DOI: 10.1002/prot.24850.
[13] Su, M.; Tan, J.; Lin, C. Y. Development of HIV-1 integrase inhibitors: recent molecular modeling perspectives. Drug Discov. Today 2015, 20 (11), 1337-48, DOI: 10.1016/j.drudis.2015.07.012.
[14] 谭建军; 张一平; 门婧睿 一种基于三维定量构效关系模型的一致性模型构建方法. CN104834831A, 2015-08-12, 2015.
[15] Zhang, X. Y.; Deng, D. J.; Tan, J. J.; He, Y.; Li, C. H.; Wang, C. X. Pharmacophore and Docking-based 3D-QSAR Studies on HIV-1 Integrase Inhibitors. Chem. Res. Chin. Univ. 2014, 30 (2), 297-305, DOI: DOI 10.1007/s40242-014-3395-5.
[16] Zhang, H. G. C.; Li, C. H.; Yang, F.; Su, J. G.; Tan, J. J.; Zhang, X. Y.; Wang, C. X. Cation-pi Interactions at Non-redundant Protein-RNA Interfaces. Biochemistry-Moscow 2014, 79 (7), 643-652, DOI: Doi 10.1134/S0006297914070062.
[17] Ma, X.; Tan, J.; Su, M.; Li, C.; Zhang, X.; Wang, C. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism. PLoS One 2014, 9 (11), e111923, DOI: 10.1371/journal.pone.0111923.
[18] Liu, W.; Tan, J. J.; Mehryar, M. M.; Teng, Z. P.; Zeng, Y. Peptide HIV fusion inhibitors: modifications and conjugations. MedChemComm 2014, 5 (10), 1472-1482, DOI: Doi 10.1039/C4md00214h.
[19] Li, S.; Liu, B.; Li, C. H.; Tan, J. J.; Zhang, X. Y.; Wang, C. X. E92A Is an Activity Recovery Mutation of HIV-1 Integrase Drug Resistance Mutation N155S. Prog. Biochem. Biophys. 2014, 41 (5), 472-479, DOI: Doi 10.3724/Sp.J.1206.2013.00300.
[20] Li, C. H.; Yang, Y. X.; Su, J. G.; Liu, B.; Tan, J. J.; Zhang, X. Y.; Wang, C. X. Allosteric Transitions of the Maltose Transporter Studied by an Elastic Network Model. Biopolymers 2014, 101 (7), 758-768, DOI: Doi 10.1002/Bip.22455.
[21] Xu, X. J.; Su, J. G.; Liu, B.; Li, C. H.; Tan, J. J.; Zhang, X. Y.; Chen, W. Z.; Wang, C. X. Reverse Virtual Screening on Persistent Organic Pollutants 4,4 '-DDE and CB-153. Acta Phys-Chim Sin 2013, 29 (10), 2276-2285, DOI: 10.3866/pku.whxb201307161.
[22] Tan, J. J.; Wang, Y.; Wang, C. X. Quantitative Structure-Activity RElationship of Anti-HIV Fusion Inhibitors by Topomer CoMFA. Journal of Beijing University of Technology 2013, 39 (2), 309-313.
[23] Tan, J. J.; Wang, C. X. The Development of Novel Inhibitors for the Treatment of HIV Infection. Curr. Pharm. Des. 2013, 19 (10), 1765-1766.
[24] Tan, J. J.; Ma, X. T.; Liu, C.; Zhang, X. Y.; Wang, C. X. The Current Status and Challenges in the Development of Fusion Inhibitors as Therapeutics for HIV-1 Infection. Curr. Pharm. Des. 2013, 19 (10), 1810-1817.
[25] Sun, X. H.; Guan, J. Q.; Tan, J. J.; Liu, C.; Wang, C. X. In Exploring quinoline ring derivatives as potent integrase inhibitors using ligand-based modeling studies, World Congress on Medical Physics and Biomedical Engineering, May 26, 2012 - May 31, 2012, Beijing, China, Springer Verlag: Beijing, China, 2013; pp 1276-1279.
[26] Ma, X. T.; Sun, X. H.; Tan, J. J.; Wang, C. X. In Development of peptide fusion inhibitors targeting HIV-1 gp41, World Congress on Medical Physics and Biomedical Engineering, May 26, 2012 - May 31, 2012, Beijing, China, Springer Verlag: Beijing, China, 2013; pp 2221-2223.
[27] Liu, X.; Tan, J. J.; Chen, W. Z.; Liu, B.; Li, S.; Wang, C. X. Support Vector Machine Applied to Predicting the Activity of HIV－1 IN Inhibitors. Journal of Beijing University of Technology 2013, 39 (4), 634-640.
[28] 谭建军; 苑红领; 曾毅; 李春华; 刘斌; 张小轶; 王存新 抑制HIV病毒与宿主细胞融合的非对映体多肽及其用途. 2014-4-16, 2013.
[29] Tan, J. J.; Liu, C.; Sun, X. H.; Cong, X. J.; Hu, L. M.; Wang, C. X.; Liang, X. J. Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase. Mini-Rev. Med. Chem. 2012, 12 (9), 875-889.
[30] Sun, X. H.; Guan, J. Q.; Tan, J. J.; Liu, C.; Wang, C. X. 3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors. SAR QSAR Environ. Res. 2012, 23 (7-8), 683-703, DOI: 10.1080/1062936x.2012.717541.
[31] Tan, J. J.; Zhang, B.; Cong, X. J.; Yang, L. F.; Liu, B.; Kong, R.; Kui, Z. Y.; Wang, C. X.; Hu, L. M. Computer-Aided Design, Synthesis, and Biological Activity Evaluation of Potent Fusion Inhibitors Targeting HIV-1 gp41. Med. Chem. 2011, 7 (4), 309-316.
[32] Tan, J. J.; Sun, X. H.; Liu, B.; Wang, C. X., Computer-aided Design, Synthesis, and Biological Activity Evaluation of Potent Fusion Inhibitors Targeting HIV-1 gp41. In 17th Inetrnational Biophysics Congress, Beijing 2011; pp 404-405.
[33] Li, P.; Liu, M.; Tan, J. J.; Zhang, X. Y.; Chen, W. Z.; Wang, C. X. Insight into the Inhibitory Mechanism and Binding Mode Between D77 and HIV-1 Integrase by Molecular Modeling Methods Journal of Biomolcular Structure and Dynamics 2011, 29 (2), 251-423.
[34] Tan, J. J.; Cong, X. J.; Hu, L. M.; Wang, C. X.; Jia, L.; Liang, X. J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov. Today 2010, 15 (5-6), 186-197, DOI: 10.1016/j.drudis.2010.01.004.
[35] Luo, Z. G.; Tan, J. J.; Zeng, Y.; Wang, C. X.; Hu, L. M. Development of Integrase Inhibitors of Quinolone Acid Derivatives for Treatment of AIDS: An Overview. Mini-Rev. Med. Chem. 2010, 10 (11), 1046-1057.
[36] Jiao, Z. G.; He, H. Q.; Zeng, C. C.; Tan, J. J.; Hu, L. M.; Wang, C. X. Design, Synthesis and Anti-HIV Integrase Evaluation of N-(5-Chloro-8-Hydroxy-2-Styrylquinolin-7-yl)Benzenesulfonamide Derivatives. Molecules 2010, 15 (3), 1903-1917, DOI: 10.3390/molecules15031903.
[37] Cong, X. J.; Tan, J. J.; Liu, M.; Chen, W. Z.; Wang, C. X. Computational Study of Binding Mode for N-substituted Pyrrole Derivatives to HIV-1 gp41. Prog. Biochem. Biophys. 2010, 37 (8), 904-915, DOI: 10.3724/sp.j.1206.2010.00110.
[38] Liu, M.; Cong, X. J.; Li, P.; Tan, J. J.; Chen, W. Z.; Wang, C. X. Study on the Inhibitory Mechanism and Binding Mode of the Hydroxycoumarin Compound NSC158393 to HIV-1 Integrase by Molecular Modeling. Biopolymers 2009, 91 (9), 700-709, DOI: 10.1002/bip.21211.
[39] Liu, M.; Su, J. G.; Kong, R.; Sun, T. G.; Tan, J. J.; Chen, W. Z.; Wang, C. X. Molecular dynamics simulations of the bacterial periplasmic heme binding proteins ShuT and PhuT. Biophys. Chem. 2008, 138 (1-2), 42-49, DOI: 10.1016/j.bpc.2008.09.001.
[40] Tan, J. J.; Chen, W. Z.; Wang, C. X. Investigating interactions between HIV-1 gp41 and inhibitors by molecular dynamics simulation and MM-PBSA/GBSA calculations. J. Mol. Struct. Theochem 2006, 766 (2-3), 77-82, DOI: 10.1016/j.theochem.2006.02.022.
[41] Kong, R.; Tan, J. J.; Ma, X. H.; Chen, W. Z.; Wang, C. X. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. Bba-Proteins Proteom 2006, 1764 (4), 766-772, DOI: 10.1016/j.bbapap.2005.12.017.
[42] Tan, J. J.; Kong, R.; Chen, W. Z.; Wang, C. X. Studies on binding free energies and the binding mode by docking and MM-PBSA in gp41-ligand complex. Mol. Simul. 2005, 31 (14-15), 1051-1056, DOI: 10.1080/08927020500447132.
[43] Tan, J. J.; Kong, R.; Wang, C. X.; Chen, W. Z. Molecular dynamics simulation on the complexes of N-terminal region of HIV-1 gp41 and its C-peptide inhibitors. J. Mol. Struct. Theochem 2004, 682 (1-3), 9-15, DOI: 10.1016/j.theochem.2004.05.016.
[44] Ma, X. H.; Zhang, X. Y.; Tan, J. J.; Chen, W. Z.; Wang, C. X. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. Acta Pharmacol. Sin. 2004, 25 (7), 950-958.
